FDG-PET/CT in the staging of local/regional metastases in breast cancer

被引:53
作者
Robertson, Ian J. [1 ]
Hand, Fiona [1 ]
Kell, Malcolm R. [1 ]
机构
[1] Mater Misericordiae Univ Hosp, Eccles Breast Screening Unit, Dublin 7, Ireland
关键词
FDG-PET/CT; Breast cancer; Local/regional metastases; POSITRON-EMISSION-TOMOGRAPHY; LYMPH-NODE BIOPSY; MANAGEMENT; SCAN;
D O I
10.1016/j.breast.2011.07.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the commonest female malignancy in the Western world and the most reliable predictor for survival is axillary lymph node metastases. Conventional staging techniques employed in breast cancer include mammography, ultrasonography, isotope bone scanning, sentinel lymph node biopsy, axillary lymph node dissection and magnetic resonance imaging. More recently FDG-PET and FDG-PET/CT have been used to complement the above methods. This review assesses the role of FOG-PET/CT in axillary staging ill patients with primary breast cancer. A PubMed search was conducted and all articles containing relevant or new information were included. Relevant studies examined identified that FOG-PET/CT has a sensitivity of 60% and a specificity of 97% in detecting lymphatic metastasis. Although positive axillary FOG-PET/CT is a good predictor of axillary disease and correlates well with SLNB, the relatively poor sensitivity (60%) must be considered for treatment planning. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:491 / 494
页数:4
相关论文
共 50 条
  • [21] Role of FDG-PET/CT in Diagnosis, Staging, Response to Treatment, and Prognosis of Pancreatic Cancer
    Grassetto, Gaia
    Rubello, Domenico
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 111 - 114
  • [22] FDG-PET for axillary lymph node staging in primary breast cancer
    Flavio Crippa
    Alberto Gerali
    Alessandra Alessi
    Roberto Agresti
    Emilio Bombardieri
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : S97 - S102
  • [23] FDG-PET in the initial staging of locally advanced breast cancer before neoadjuvant chemotherapy
    Fosse, P.
    Girault, S.
    Capitain, O.
    Valo, I.
    Bouchet, F.
    Vervueren, L.
    Lacoeuille, F.
    Couturier, O.
    Morel, O.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2012, 36 (02): : 69 - 76
  • [24] Breast cancer with low FDG uptake: Characterization by means of dual-time point FDG-PET/CT
    Zytoon, Ashraf Anas
    Murakami, Koji
    El-Kholy, Mohamed Ramdan
    El-Shorbagy, Emad
    Ebied, Osama
    EUROPEAN JOURNAL OF RADIOLOGY, 2009, 70 (03) : 530 - 538
  • [25] Breast cancer: initial workup and staging with FDG PET/CT
    David Groheux
    Elif Hindie
    Clinical and Translational Imaging, 2021, 9 : 221 - 231
  • [26] Initial experience with FDG-PET/CT in the evaluation of breast cancer
    Tatsumi, M
    Cohade, C
    Mourtzikos, K
    Fishman, EK
    Wahl, RL
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (03) : 254 - 262
  • [27] Initial experience with FDG-PET/CT in the evaluation of breast cancer
    Mitsuaki Tatsumi
    Christian Cohade
    Karen A. Mourtzikos
    Elliot K. Fishman
    Richard L. Wahl
    European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33 : 254 - 262
  • [28] 18FDG-PET/CT in staging and measuring the efficacy of neoadjuvant chemotherapy in breast cancer
    Groheux, D.
    Hindie, E.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2015, 39 (03): : 315 - 326
  • [29] Impact of FDG-PET for staging of oesophageal cancer
    Imdahl, A
    Hentschel, M
    Kleimaier, M
    Hopt, UT
    Brink, I
    LANGENBECKS ARCHIVES OF SURGERY, 2004, 389 (04) : 283 - 288
  • [30] Progressive Osteoblastic Bone Metastases in Breast Cancer Negative on FDG-PET
    Huyge, Valrie
    Garcia, Camilo
    Vanderstappen, Anja
    Alexiou, Jean
    Gil, Thierry
    Flamen, Patrick
    CLINICAL NUCLEAR MEDICINE, 2009, 34 (07) : 417 - 420